MicroRNA regulation of epithelial to mesenchymal transition

Journal of Clinical Medicine

Volumn 5, Issue 1, 2016, Pages

  Abba, Mohammed L ^a   Patil, Nitin ^a   Leupold, Jörg Hendrik ^a   Allgayer, Heike ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; EMT; MET; MicroRNAs; Transcription factor

Indexed keywords

BETA CATENIN; BETA1 INTEGRIN; CADHERIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GEFITINIB; GELATINASE A; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; HISTONE METHYLTRANSFERASE; INTERSTITIAL COLLAGENASE; KRUPPEL LIKE FACTOR 4; MICRORNA; MICRORNA 141; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; NERVE CELL ADHESION MOLECULE; PLAKOPHILIN; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SMAD PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; VASCULOTROPIN; VIMENTIN;

CANCER STAGING; CELL INVASION; CELL MIGRATION; COLONY FORMATION; DNA METHYLATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PHENOTYPE; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 85048764620     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5010008     Document Type: Review

References (198)

1. Cavey, M.; Lecuit, T. Molecular bases of cell-cell junctions stability and dynamics. Cold Spring Harb. Perspect. Biol. 2009, 1, a002998
2. Zaravinos, A. The regulatory role of micrornas in emt and cancer. J. Oncol. 2015, 2015, 865816
3. Tam, W.L.; Weinberg, R.A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 2013, 19, 1438–1449
4. Liu, W.; Vivian, C.J.; Brinker, A.E.; Hampton, K.R.; Lianidou, E.; Welch, D.R. Microenvironmental influences on metastasis suppressor expression and function during a metastatic cell’s journey. Cancer Microenviron. 2014, 7, 117–131
5. De Craene, B.; Berx, G. Regulatory networks defining emt during cancer initiation and progression. Nat. Rev. Cancer 2013, 13, 97–110
6. Bedi, U.; Mishra, V.K.; Wasilewski, D.; Scheel, C.; Johnsen, S.A. Epigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget 2014, 5, 2016–2029. [CrossRef] [PubMed]
7. Demirkan, B. The roles of epithelial-to-mesenchymal transition (emt) and mesenchymal-to-epithelial transition (met) in breast cancer bone metastasis: Potential targets for prevention and treatment. J. Clin. Med. 2013, 2, 264–282. [CrossRef] [PubMed]
8. Corallino, S.; Malabarba, M.G.; Zobel, M.; Di Fiore, P.P.; Scita, G. Epithelial-to-mesenchymal plasticity harnesses endocytic circuitries. Front. Oncol. 2015, 5, 45. [CrossRef] [PubMed]
9. Chou, Y.S.; Yang, M.H. Epithelial-mesenchymal transition-related factors in solid tumor and hematological malignancy. J. Chin. Med. Assoc. 2015, 78, 438–445. [CrossRef] [PubMed]
10. Cannito, S.; Novo, E.; di Bonzo, L.V.; Busletta, C.; Colombatto, S.; Parola, M. Epithelial-mesenchymal transition: From molecular mechanisms, redox regulation to implications in human health and disease. Antioxid. Redox Signal 2010, 12, 1383–1430. [CrossRef] [PubMed]
11. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196. [PubMed]
12. Nieto, M.A. Epithelial plasticity: A common theme in embryonic and cancer cells. Science 2013, 342, 1234850. [PubMed]
13. Jolly, M.K.; Boareto, M.; Huang, B.; Jia, D.; Lu, M.; Ben-Jacob, E.; Onuchic, J.N.; Levine, H. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front. Oncol. 2015, 5, 155. [CrossRef] [PubMed]
14. Revenu, C.; Gilmour, D. Emt 2.0: Shaping epithelia through collective migration. Curr. Opin. Genet. Dev. 2009, 19, 338–342. [CrossRef] [PubMed]
15. Theveneau, E.; Marchant, L.; Kuriyama, S.; Gull, M.; Moepps, B.; Parsons, M.; Mayor, R. Collective chemotaxis requires contact-dependent cell polarity. Dev. Cell 2010, 19, 39–53. [CrossRef] [PubMed]
16. Ninov, N.; Chiarelli, D.A.; Martin-Blanco, E. Extrinsic and intrinsic mechanisms directing epithelial cell sheet replacement during drosophila metamorphosis. Development 2007, 134, 367–379. [CrossRef] [PubMed]
17. Nakashima, Y.; Yoshinaga, K.; Kitao, H.; Ando, K.; Kimura, Y.; Saeki, H.; Oki, E.; Morita, M.; Kakeji, Y.; Hirahashi, M., et al. Podoplanin is expressed at the invasive front of esophageal squamous cell carcinomas and is involved in collective cell invasion. Cancer Sci. 2013, 104, 1718–1725. [CrossRef] [PubMed]
18. Su, S.; Liu, Q.; Chen, J.; Chen, J.; Chen, F.; He, C.; Huang, D.; Wu, W.; Lin, L.; Huang, W., et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014, 25, 605–620. [CrossRef] [PubMed]
19. Sarrio, D.; Rodriguez-Pinilla, S.M.; Hardisson, D.; Cano, A.; Moreno-Bueno, G.; Palacios, J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008, 68, 989–997. [CrossRef] [PubMed]
20. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428. [CrossRef] [PubMed]
21. Kalluri, R. Emt: When epithelial cells decide to become mesenchymal-like cells. J. Clin. Investig. 2009, 119, 1417–1419. [CrossRef] [PubMed]
22. Klymkowsky, M.W.; Savagner, P. Epithelial-mesenchymal transition: A cancer researcher’s conceptual friend and foe. Am. J. Pathol. 2009, 174, 1588–1593. [CrossRef] [PubMed]
23. Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9, 265–273. [CrossRef] [PubMed]
24. Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871–890. [CrossRef] [PubMed]
25. Yilmaz, M.; Christofori, G. Emt, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28, 15–33. [CrossRef] [PubMed]
26. Barrallo-Gimeno, A.; Nieto, M.A. The snail genes as inducers of cell movement and survival: Implications in development and cancer. Development 2005, 132, 3151–3161. [CrossRef] [PubMed]
27. Ye, X.; Weinberg, R.A. Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol. 2015, 25, 675–686. [CrossRef] [PubMed]
28. Mudduluru, G.; Abba, M.; Batliner, J.; Patil, N.; Scharp, M.; Lunavat, T.R.; Leupold, J.H.; Oleksiuk, O.; Juraeva, D.; Thiele, W., et al. A systematic approach to defining the microrna landscape in metastasis. Cancer Res. 2015, 75, 3010–3019. [CrossRef] [PubMed]
29. Aigner, K.; Dampier, B.; Descovich, L.; Mikula, M.; Sultan, A.; Schreiber, M.; Mikulits, W.; Brabletz, T.; Strand, D.; Obrist, P., et al. The transcription factor zeb1 (deltaef1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007, 26, 6979–6988. [CrossRef] [PubMed]
30. Bolos, V.; Peinado, H.; Perez-Moreno, M.A.; Fraga, M.F.; Esteller, M.; Cano, A. The transcription factor slug represses e-cadherin expression and induces epithelial to mesenchymal transitions: A comparison with snail and e47 repressors. J. Cell. Sci. 2003, 116, 499–511. [CrossRef] [PubMed]
31. Grooteclaes, M.L.; Frisch, S.M. Evidence for a function of ctbp in epithelial gene regulation and anoikis. Oncogene 2000, 19, 3823–3828. [CrossRef] [PubMed]
32. Hajra, K.M.; Fearon, E.R. Cadherin and catenin alterations in human cancer. Genes Chromosom. Cancer 2002, 34, 255–268. [CrossRef] [PubMed]
33. Hajra, K.M.; Chen, D.Y.; Fearon, E.R. The slug zinc-finger protein represses e-cadherin in breast cancer. Cancer Res. 2002, 62, 1613–1618. [PubMed]
34. Huber, M.A.; Kraut, N.; Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell. Biol. 2005, 17, 548–558. [CrossRef] [PubMed]
35. Batlle, E.; Sancho, E.; Franci, C.; Dominguez, D.; Monfar, M.; Baulida, J.; Garcia De Herreros, A. The transcription factor snail is a repressor of e-cadherin gene expression in epithelial tumour cells. Nat. Cell. Biol. 2000, 2, 84–89. [CrossRef] [PubMed]
36. Cano, A.; Perez-Moreno, M.A.; Rodrigo, I.; Locascio, A.; Blanco, M.J.; del Barrio, M.G.; Portillo, F.; Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing e-cadherin expression. Nat. Cell. Biol. 2000, 2, 76–83. [CrossRef] [PubMed]
37. Peinado, H.; Olmeda, D.; Cano, A. Snail, zeb and bhlh factors in tumour progression: An alliance against the epithelial phenotype? Nat. Rev. Cancer 2007, 7, 415–428. [CrossRef] [PubMed]
38. Yoshida, J.; Horiuchi, A.; Kikuchi, N.; Hayashi, A.; Osada, R.; Ohira, S.; Shiozawa, T.; Konishi, I. Changes in the expression of e-cadherin repressors, snail, slug, sip1, and twist, in the development and progression of ovarian carcinoma: The important role of snail in ovarian tumorigenesis and progression. Med. Mol. Morphol. 2009, 42, 82–91. [CrossRef] [PubMed]
39. Yang, J.; Mani, S.A.; Donaher, J.L.; Ramaswamy, S.; Itzykson, R.A.; Come, C.; Savagner, P.; Gitelman, I.; Richardson, A.; Weinberg, R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117, 927–939. [CrossRef] [PubMed]
40. Byles, V.; Zhu, L.; Lovaas, J.D.; Chmilewski, L.K.; Wang, J.; Faller, D.V.; Dai, Y. Sirt1 induces emt by cooperating with emt transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 2012, 31, 4619–4629. [CrossRef] [PubMed]
41. Dave, N.; Guaita-Esteruelas, S.; Gutarra, S.; Frias, A.; Beltran, M.; Peiro, S.; de Herreros, A.G. Functional cooperation between snail1 and twist in the regulation of zeb1 expression during epithelial to mesenchymal transition. J. Biol. Chem. 2011, 286, 12024–12032. [CrossRef] [PubMed]
42. Peinado, H.; Portillo, F.; Cano, A. Transcriptional regulation of cadherins during development and carcinogenesis. Int. J. Dev. Biol. 2004, 48, 365–375. [CrossRef] [PubMed]
43. Wheelock, M.J.; Shintani, Y.; Maeda, M.; Fukumoto, Y.; Johnson, K.R. Cadherin switching. J. Cell. Sci. 2008, 121, 727–735. [CrossRef] [PubMed]
44. Schickel, R.; Boyerinas, B.; Park, S.M.; Peter, M.E. Micrornas: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008, 27, 5959–5974. [CrossRef] [PubMed]
45. Garofalo, M.; Croce, C.M. Micrornas: Master regulators as potential therapeutics in cancer. Annu. Rev. Pharmacol. Toxicol. 2011, 51, 25–43. [CrossRef] [PubMed]
46. Bailey, S.G.; Sanchez-Elsner, T.; Stephanou, A.; Cragg, M.S.; Townsend, P.A. Regulating the genome surveillance system: Mirnas and the p53 super family. Apoptosis 2010, 15, 541–552. [CrossRef] [PubMed]
47. Baehrecke, E.H. Mirnas: Micro managers of programmed cell death. Curr. Biol. 2003, 13, R473–R475. [CrossRef]
48. Takeishi, Y. Biomarkers in heart failure. Int. Heart J. 2014, 55, 474–481. [CrossRef] [PubMed]
49. Stellato, C. Posttranscriptional gene regulation: Novel pathways for glucocorticoids’ anti-inflammatory action. Transl. Med. UniSa. 2012, 3, 67–73. [PubMed]
50. States, J.C.; Srivastava, S.; Chen, Y.; Barchowsky, A. Arsenic and cardiovascular disease. Toxicol. Sci. 2009, 107, 312–323. [CrossRef] [PubMed]
51. Sinkovics, J.G. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microrna/DNA interactions (review). Int. J. Oncol. 2012, 40, 305–349. [CrossRef] [PubMed]
52. Ranjha, R.; Paul, J. Micro-rnas in inflammatory diseases and as a link between inflammation and cancer. Inflamm. Res. 2013, 62, 343–355. [CrossRef] [PubMed]
53. Malemud, C.J. The discovery of novel experimental therapies for inflammatory arthritis. Mediators Inflamm. 2009, 2009, 698769. [CrossRef] [PubMed]
54. Lukiw, W.J.; Andreeva, T.V.; Grigorenko, A.P.; Rogaev, E.I. Studying micro rna function and dysfunction in alzheimer’s disease. Front Genet. 2012, 3, 327. [CrossRef] [PubMed]
55. Kim, Y.; Eom, S.; Park, D.; Kim, H.; Jeoung, D. The hyaluronic acid-hdac3-mirna network in allergic inflammation. Front Immunol. 2015, 6, 210. [CrossRef] [PubMed]
56. Hamar, P. Role of regulatory micro rnas in type 2 diabetes mellitus-related inflammation. Nucleic Acid Ther. 2012, 22, 289–294. [PubMed]
57. Deb, R.; Kumar, A.; Chakraborty, S.; Verma, A.K.; Tiwari, R.; Dhama, K.; Singh, U.; Kumar, S. Trends in diagnosis and control of bovine mastitis: A review. Pak. J. Biol. Sci. 2013, 16, 1653–1661. [CrossRef] [PubMed]
58. Ather, M.H.; Siddiqui, T. The genetics of neuroendocrine prostate cancers: A review of current and emerging candidates. Appl. Clin. Genet. 2012, 5, 105–110. [CrossRef] [PubMed]
59. Alexander, M.; O’Connell, R.M. Noncoding rnas and chronic inflammation: Micro-managing the fire within. Bioessays 2015, 37, 1005–1015. [CrossRef] [PubMed]
60. Oleksiuk, O.; Abba, M.; Tezcan, K.C.; Schaufler, W.; Bestvater, F.; Patil, N.; Birk, U.; Hafner, M.; Altevogt, P.; Cremer, C., et al. Single-molecule localization microscopy allows for the analysis of cancer metastasis-specific mirna distribution on the nanoscale. Oncotarget 2015
61. Utikal, J.; Abba, M.; Novak, D.; Moniuszko, M.; Allgayer, H. Function and significance of micrornas in benign and malignant human stem cells. Semin. Cancer Biol. 2015, 35, 200–211. [CrossRef] [PubMed]
62. Abba, M.; Patil, N.; Allgayer, H. Micrornas in the regulation of mmps and metastasis. Cancers (Basel) 2014, 6, 625–645. [CrossRef] [PubMed]
63. Abba, M.; Mudduluru, G.; Allgayer, H. Micrornas in cancer: Small molecules, big chances. Anticancer Agents Med. Chem. 2012, 12, 733–743. [CrossRef] [PubMed]
64. Mobley, A.K.; Braeuer, R.R.; Kamiya, T.; Shoshan, E.; Bar-Eli, M. Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev. 2012, 31, 621–632. [CrossRef] [PubMed]
65. Hoesel, B.; Schmid, J.A. The complexity of nf-kappab signaling in inflammation and cancer. Mol. Cancer 2013, 12, 86. [CrossRef] [PubMed]
66. Boldin, M.P.; Baltimore, D. Micrornas, new effectors and regulators of nf-kappab. Immunol. Rev. 2012, 246, 205–220. [CrossRef] [PubMed]
67. Liao, J.M.; Cao, B.; Zhou, X.; Lu, H. New insights into p53 functions through its target micrornas. J. Mol. Cell. Biol. 2014, 6, 206–213. [CrossRef] [PubMed]
68. Rokavec, M.; Li, H.; Jiang, L.; Hermeking, H. The p53/mir-34 axis in development and disease. J. Mol. Cell. Biol. 2014, 6, 214–230. [CrossRef] [PubMed]
69. Zhao, J.J.; Carrasco, R.D. Crosstalk between microrna30a/b/c/d/e-5p and the canonical wnt pathway: Implications for multiple myeloma therapy. Cancer Res. 2014, 74, 5351–5358. [CrossRef] [PubMed]
70. Zhang, J.; Ma, L. Microrna control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev. 2012, 31, 653–662. [CrossRef] [PubMed]
71. Romero-Cordoba, S.L.; Salido-Guadarrama, I.; Rodriguez-Dorantes, M.; Hidalgo-Miranda, A. Mirna biogenesis: Biological impact in the development of cancer. Cancer Biol. Ther. 2014, 15, 1444–1455. [CrossRef] [PubMed]
72. Hu, Y.; Tang, H. Micrornas regulate the epithelial to mesenchymal transition (emt) in cancer progression. Microrna 2014, 3, 108–117. [CrossRef] [PubMed]
73. Hao, J.; Zhang, Y.; Deng, M.; Ye, R.; Zhao, S.; Wang, Y.; Li, J.; Zhao, Z. Microrna control of epithelial-mesenchymal transition in cancer stem cells. Int. J. Cancer. 2014, 135, 1019–1027. [CrossRef] [PubMed]
74. Feng, X.; Wang, Z.; Fillmore, R.; Xi, Y. Mir-200, a new star mirna in human cancer. Cancer Lett. 2014, 344, 166–173. [CrossRef] [PubMed]
75. Rusek, A.M.; Abba, M.; Eljaszewicz, A.; Moniuszko, M.; Niklinski, J.; Allgayer, H. Microrna modulators of epigenetic regulation, the tumor microenvironment and the immune system in lung cancer. Mol. Cancer 2015, 14, 34. [CrossRef] [PubMed]
76. Mimeault, M.; Batra, S.K. Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. Cancer Epidemiol. Biomarkers Prev. 2014, 23, 234–254. [CrossRef] [PubMed]
77. Zheng, H.; Kang, Y. Multilayer control of the emt master regulators. Oncogene 2014, 33, 1755–1763. [CrossRef] [PubMed]
78. Tania, M.; Khan, M.A.; Fu, J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014, 35, 7335–7342. [CrossRef] [PubMed]
79. Son, H.; Moon, A. Epithelial-mesenchymal transition and cell invasion. Toxicol. Res. 2010, 26, 245–252. [CrossRef] [PubMed]
80. Vandewalle, C.; Van Roy, F.; Berx, G. The role of the zeb family of transcription factors in development and disease. Cell. Mol. Life Sci. 2009, 66, 773–787. [CrossRef] [PubMed]
81. Sanchez-Tillo, E.; Liu, Y.; de Barrios, O.; Siles, L.; Fanlo, L.; Cuatrecasas, M.; Darling, D.S.; Dean, D.C.; Castells, A.; Postigo, A. Emt-activating transcription factors in cancer: Beyond emt and tumor invasiveness. Cell. Mol. Life Sci. 2012, 69, 3429–3456. [CrossRef] [PubMed]
82. Hill, L.; Browne, G.; Tulchinsky, E. Zeb/mir-200 feedback loop: At the crossroads of signal transduction in cancer. Int. J. Cancer 2013, 132, 745–754. [CrossRef] [PubMed]
83. Lai-Cheong, J.E.; Arita, K.; McGrath, J.A. Genetic diseases of junctions. J. Investig. Dermatol. 2007, 127, 2713–2725. [CrossRef] [PubMed]
84. Schmidt, A.; Heid, H.W.; Schafer, S.; Nuber, U.A.; Zimbelmann, R.; Franke, W.W. Desmosomes and cytoskeletal architecture in epithelial differentiation: Cell type-specific plaque components and intermediate filament anchorage. Eur. J. Cell. Biol. 1994, 65, 229–245. [PubMed]
85. Tepass, U. Claudin complexities at the apical junctional complex. Nat. Cell. Biol. 2003, 5, 595–597. [CrossRef] [PubMed]
86. Katoh, M. Epithelial-mesenchymal transition in gastric cancer (review). Int. J. Oncol. 2005, 27, 1677–1683. [PubMed]
87. McConkey, D.J.; Choi, W.; Marquis, L.; Martin, F.; Williams, M.B.; Shah, J.; Svatek, R.; Das, A.; Adam, L.; Kamat, A., et al. Role of epithelial-to-mesenchymal transition (emt) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009, 28, 335–344. [CrossRef] [PubMed]
88. Yasumi, M.; Sakisaka, T.; Hoshino, T.; Kimura, T.; Sakamoto, Y.; Yamanaka, T.; Ohno, S.; Takai, Y. Direct binding of lgl2 to lgn during mitosis and its requirement for normal cell division. J. Biol. Chem. 2005, 280, 6761–6765. [CrossRef] [PubMed]
89. Musch, A.; Cohen, D.; Yeaman, C.; Nelson, W.J.; Rodriguez-Boulan, E.; Brennwald, P.J. Mammalian homolog of drosophila tumor suppressor lethal (2) giant larvae interacts with basolateral exocytic machinery in madin-darby canine kidney cells. Mol. Biol. Cell 2002, 13, 158–168. [CrossRef] [PubMed]
90. Elsum, I.A.; Martin, C.; Humbert, P.O. Scribble regulates an emt polarity pathway through modulation of mapk-erk signaling to mediate junction formation. J. Cell. Sci. 2013, 126, 3990–3999. [CrossRef] [PubMed]
91. Burk, U.; Schubert, J.; Wellner, U.; Schmalhofer, O.; Vincan, E.; Spaderna, S.; Brabletz, T. A reciprocal repression between zeb1 and members of the mir-200 family promotes emt and invasion in cancer cells. EMBO Rep. 2008, 9, 582–589. [CrossRef] [PubMed]
92. Gregory, P.A.; Bert, A.G.; Paterson, E.L.; Barry, S.C.; Tsykin, A.; Farshid, G.; Vadas, M.A.; Khew-Goodall, Y.; Goodall, G.J. The mir-200 family and mir-205 regulate epithelial to mesenchymal transition by targeting zeb1 and sip1. Nat. Cell. Biol. 2008, 10, 593–601. [CrossRef] [PubMed]
93. Korpal, M.; Lee, E.S.; Hu, G.; Kang, Y. The mir-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of e-cadherin transcriptional repressors zeb1 and zeb2. J. Biol. Chem. 2008, 283, 14910–14914. [CrossRef] [PubMed]
94. Park, S.M.; Gaur, A.B.; Lengyel, E.; Peter, M.E. The mir-200 family determines the epithelial phenotype of cancer cells by targeting the e-cadherin repressors zeb1 and zeb2. Genes Dev. 2008, 22, 894–907. [CrossRef] [PubMed]
95. Kim, T.; Veronese, A.; Pichiorri, F.; Lee, T.J.; Jeon, Y.J.; Volinia, S.; Pineau, P.; Marchio, A.; Palatini, J.; Suh, S.S., et al. P53 regulates epithelial-mesenchymal transition through micrornas targeting zeb1 and zeb2. J. Exp. Med. 2011, 208, 875–883. [CrossRef] [PubMed]
96. Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.; Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the mir-130b-zeb1 axis. Oncogene 2013, 32, 3286–3295. [CrossRef] [PubMed]
97. Qiu, G.; Lin, Y.; Zhang, H.; Wu, D. Mir-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting zeb1 and zeb2. Biochem. Biophys. Res. Commun. 2015, 463, 315–321. [CrossRef] [PubMed]
98. Lee, J.Y.; Park, M.K.; Park, J.H.; Lee, H.J.; Shin, D.H.; Kang, Y.; Lee, C.H.; Kong, G. Loss of the polycomb protein mel-18 enhances the epithelial-mesenchymal transition by zeb1 and zeb2 expression through the downregulation of mir-205 in breast cancer. Oncogene 2014, 33, 1325–1335. [CrossRef] [PubMed]
99. Matsushima, K.; Isomoto, H.; Yamaguchi, N.; Inoue, N.; Machida, H.; Nakayama, T.; Hayashi, T.; Kunizaki, M.; Hidaka, S.; Nagayasu, T., et al. Mirna-205 modulates cellular invasion and migration via regulating zinc finger e-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J. Transl. Med. 2011, 9, 30. [CrossRef] [PubMed]
100. Majid, S.; Dar, A.A.; Saini, S.; Deng, G.; Chang, I.; Greene, K.; Tanaka, Y.; Dahiya, R.; Yamamura, S. Microrna-23b functions as a tumor suppressor by regulating zeb1 in bladder cancer. PLoS ONE 2013, 8, e67686. [CrossRef] [PubMed]
101. Yokobori, T.; Suzuki, S.; Tanaka, N.; Inose, T.; Sohda, M.; Sano, A.; Sakai, M.; Nakajima, M.; Miyazaki, T.; Kato, H., et al. Mir-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the emt inducer zeb1. Cancer Sci. 2013, 104, 48–54. [CrossRef] [PubMed]
102. Jin, M.; Yang, Z.; Ye, W.; Xu, H.; Hua, X. Microrna-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor zeb1. PLoS ONE 2014, 9, e103965. [CrossRef] [PubMed]
103. Lee, C.G.; McCarthy, S.; Gruidl, M.; Timme, C.; Yeatman, T.J. Microrna-147 induces a mesenchymalto- epithelial transition (met) and reverses egfr inhibitor resistance. PLoS ONE 2014, 9, e84597. [CrossRef] [PubMed]
104. Qu, J.; Li, M.; An, J.; Zhao, B.; Zhong, W.; Gu, Q.; Cao, L.; Yang, H.; Hu, C. Microrna-33b inhibits lung adenocarcinoma cell growth, invasion, and epithelial-mesenchymal transition by suppressing wnt/beta-catenin/zeb1 signaling. Int. J. Oncol. 2015. [CrossRef] [PubMed]
105. Yanaka, Y.; Muramatsu, T.; Uetake, H.; Kozaki, K.I.; Inazawa, J. Mir-544a induces epithelial-mesenchymal transition through the activation of wnt signaling pathway in gastric cancer. Carcinogenesis 2015. [CrossRef] [PubMed]
106. Li, X.L.; Hara, T.; Choi, Y.; Subramanian, M.; Francis, P.; Bilke, S.; Walker, R.L.; Pineda, M.; Zhu, Y.; Yang, Y., et al. A p21-zeb1 complex inhibits epithelial-mesenchymal transition through the microrna 183-96-182 cluster. Mol. Cell. Biol. 2014, 34, 533–550. [CrossRef] [PubMed]
107. White, E.J.; Brewer, G.; Wilson, G.M. Post-transcriptional control of gene expression by auf1: Mechanisms, physiological targets, and regulation. Biochim. Biophys. Acta. 2013, 1829, 680–688. [CrossRef] [PubMed]
108. Al-Khalaf, H.H.; Aboussekhra, A. Microrna-141 and microrna-146b-5p inhibit the prometastatic mesenchymal characteristics through the rna-binding protein auf1 targeting the transcription factor zeb1 and the protein kinase akt. J. Biol. Chem. 2014, 289, 31433–31447. [CrossRef] [PubMed]
109. Zhao, S.; Zhang, Y.; Zheng, X.; Tu, X.; Li, H.; Chen, J.; Zang, Y.; Zhang, J. Loss of microrna-101 promotes epithelial to mesenchymal transition in hepatocytes. J. Cell. Physiol. 2015, 230, 2706–2717. [CrossRef] [PubMed]
110. Zhou, J.; Xie, M.; Shi, Y.; Luo, B.; Gong, G.; Li, J.; Wang, J.; Zhao, W.; Zi, Y.; Wu, X., et al. Microrna-153 functions as a tumor suppressor by targeting set7 and zeb2 in ovarian cancer cells. Oncol. Rep. 2015, 34, 111–120. [PubMed]
111. Huang, N.; Wu, Z.; Lin, L.; Zhou, M.; Wang, L.; Ma, H.; Xia, J.; Bin, J.; Liao, Y.; Liao, W. Mir-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting zeb2 and macc1/met/akt signaling. Oncotarget 2015, 6, 15222–15234. [CrossRef] [PubMed]
112. Tan, J.; Qiu, K.; Li, M.; Liang, Y. Double-negative feedback loop between long non-coding rna tug1 and mir-145 promotes epithelial to mesenchymal transition and radioresistance in human bladder cancer cells. FEBS Lett. 2015, 589, 3175–3181. [CrossRef] [PubMed]
113. Ren, D.; Wang, M.; Guo, W.; Huang, S.; Wang, Z.; Zhao, X.; Du, H.; Song, L.; Peng, X. Double-negative feedback loop between zeb2 and mir-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. Cell Tissue Res. 2014, 358, 763–778. [CrossRef] [PubMed]
114. Zheng, Y.B.; Luo, H.P.; Shi, Q.; Hao, Z.N.; Ding, Y.; Wang, Q.S.; Li, S.B.; Xiao, G.C.; Tong, S.L. Mir-132 inhibits colorectal cancer invasion and metastasis via directly targeting zeb2. World J. Gastroenterol. 2014, 20, 6515–6522. [CrossRef] [PubMed]
115. You, J.; Li, Y.; Fang, N.; Liu, B.; Zu, L.; Chang, R.; Li, X.; Zhou, Q. Mir-132 suppresses the migration and invasion of lung cancer cells via targeting the emt regulator zeb2. PLoS ONE 2014, 9, e91827. [CrossRef] [PubMed]
116. Liu, X.; Wang, C.; Chen, Z.; Jin, Y.; Wang, Y.; Kolokythas, A.; Dai, Y.; Zhou, X. Microrna-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem. J. 2011, 440, 23–31. [CrossRef] [PubMed]
117. Stinson, S.; Lackner, M.R.; Adai, A.T.; Yu, N.; Kim, H.J.; O’Brien, C.; Spoerke, J.; Jhunjhunwala, S.; Boyd, Z.; Januario, T., et al. Mir-221/222 targeting of trichorhinophalangeal 1 (trps1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci. Signal 2011, 4, pt5. [PubMed]
118. Stinson, S.; Lackner, M.R.; Adai, A.T.; Yu, N.; Kim, H.J.; O’Brien, C.; Spoerke, J.; Jhunjhunwala, S.; Boyd, Z.; Januario, T., et al. Trps1 targeting by mir-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci. Signal 2011, 4, ra41. [PubMed]
119. Wang, Y.; Zhou, B.P. Epithelial-mesenchymal transition—A hallmark of breast cancer metastasis. Cancer Hallm. 2013, 1, 38–49. [CrossRef] [PubMed]
120. Wang, Y.; Shi, J.; Chai, K.; Ying, X.; Zhou, B.P. The role of snail in emt and tumorigenesis. Curr. Cancer Drug Targets 2013, 13, 963–972. [CrossRef] [PubMed]
121. Lin, Y.; Dong, C.; Zhou, B.P. Epigenetic regulation of emt: The snail story. Curr. Pharm. Des. 2014, 20, 1698–1705. [CrossRef] [PubMed]
122. Baulida, J.; Garcia de Herreros, A. Snail1-driven plasticity of epithelial and mesenchymal cells sustains cancer malignancy. Biochim. Biophys. Acta. 2015, 1856, 55–61. [CrossRef] [PubMed]
123. Chiang, C.; Ayyanathan, K. Snail/gfi-1 (snag) family zinc finger proteins in transcription regulation, chromatin dynamics, cell signaling, development, and disease. Cytokine Growth Factor. Rev. 2013, 24, 123–131. [CrossRef] [PubMed]
124. Kataoka, H.; Murayama, T.; Yokode, M.; Mori, S.; Sano, H.; Ozaki, H.; Yokota, Y.; Nishikawa, S.; Kita, T. A novel snail-related transcription factor smuc regulates basic helix-loop-helix transcription factor activities via specific e-box motifs. Nucleic Acids Res. 2000, 28, 626–633. [CrossRef] [PubMed]
125. Moreno-Bueno, G.; Cubillo, E.; Sarrio, D.; Peinado, H.; Rodriguez-Pinilla, S.M.; Villa, S.; Bolos, V.; Jorda, M.; Fabra, A.; Portillo, F., et al. Genetic profiling of epithelial cells expressing e-cadherin repressors reveals a distinct role for snail, slug, and e47 factors in epithelial-mesenchymal transition. Cancer Res. 2006, 66, 9543–9556. [CrossRef] [PubMed]
126. Olmeda, D.; Montes, A.; Moreno-Bueno, G.; Flores, J.M.; Portillo, F.; Cano, A. Snai1 and snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. Oncogene 2008, 27, 4690–4701. [CrossRef] [PubMed]
127. Diaz-Lopez, A.; Moreno-Bueno, G.; Cano, A. Role of microrna in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag. Res. 2014, 6, 205–216. [PubMed]
128. Diaz-Lopez, A.; Diaz-Martin, J.; Moreno-Bueno, G.; Cuevas, E.P.; Santos, V.; Olmeda, D.; Portillo, F.; Palacios, J.; Cano, A. Zeb1 and snail1 engage mir-200f transcriptional and epigenetic regulation during emt. J. Int. Cancer 2015, 136, E62–E73. [CrossRef] [PubMed]
129. Diaz-Martin, J.; Diaz-Lopez, A.; Moreno-Bueno, G.; Castilla, M.A.; Rosa-Rosa, J.M.; Cano, A.; Palacios, J. A core microrna signature associated with inducers of the epithelial-to-mesenchymal transition. J. Pathol. 2014, 232, 319–329. [CrossRef] [PubMed]
130. Kumarswamy, R.; Mudduluru, G.; Ceppi, P.; Muppala, S.; Kozlowski, M.; Niklinski, J.; Papotti, M.; Allgayer, H. Microrna-30a inhibits epithelial-to-mesenchymal transition by targeting snai1 and is downregulated in non-small cell lung cancer. J. Int. Cancer 2012, 130, 2044–2053. [CrossRef] [PubMed]
131. Liu, Z.; Tu, K.; Liu, Q. Effects of microrna-30a on migration, invasion and prognosis of hepatocellular carcinoma. FEBS Lett. 2014, 588, 3089–3097. [CrossRef] [PubMed]
132. Kourtidis, A.; Ngok, S.P.; Pulimeno, P.; Feathers, R.W.; Carpio, L.R.; Baker, T.R.; Carr, J.M.; Yan, I.K.; Borges, S.; Perez, E.A., et al. Distinct e-cadherin-based complexes regulate cell behaviour through mirna processing or src and p120 catenin activity. Nat. Cell. Biol. 2015, 17, 1145–1157. [CrossRef] [PubMed]
133. Kim, N.H.; Kim, H.S.; Li, X.Y.; Lee, I.; Choi, H.S.; Kang, S.E.; Cha, S.Y.; Ryu, J.K.; Yoon, D.; Fearon, E.R., et al. A p53/mirna-34 axis regulates snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol. 2011, 195, 417–433. [CrossRef] [PubMed]
134. Xu, Q.; Sun, Q.; Zhang, J.; Yu, J.; Chen, W.; Zhang, Z. Downregulation of mir-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. Carcinogenesis 2013, 34, 539–549. [CrossRef] [PubMed]
135. Zhang, Z.; Sun, J.; Bai, Z.; Li, H.; He, S.; Chen, R.; Che, X. Microrna-153 acts as a prognostic marker in gastric cancer and its role in cell migration and invasion. Onco. Targets. Ther. 2015, 8, 357–364. [PubMed]
136. Bai, Z.; Sun, J.; Wang, X.; Wang, H.; Pei, H.; Zhang, Z. Microrna-153 is a prognostic marker and inhibits cell migration and invasion by targeting snai1 in human pancreatic ductal adenocarcinoma. Oncol. Rep. 2015, 34, 595–602. [CrossRef] [PubMed]
137. Suzuki, T.; Mizutani, K.; Minami, A.; Nobutani, K.; Kurita, S.; Nagino, M.; Shimono, Y.; Takai, Y. Suppression of the tgf-beta1-induced protein expression of snai1 and n-cadherin by mir-199a. Genes Cells 2014, 19, 667–675. [CrossRef] [PubMed]
138. Yang, D.; Sun, Y.; Hu, L.; Zheng, H.; Ji, P.; Pecot, C.V.; Zhao, Y.; Reynolds, S.; Cheng, H.; Rupaimoole, R., et al. Integrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013, 23, 186–199. [CrossRef] [PubMed]
139. Sun, Y.; Hu, L.; Zheng, H.; Bagnoli, M.; Guo, Y.; Rupaimoole, R.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Ji, P.; Chen, K., et al. Mir-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J. Pathol. 2015, 235, 25–36. [CrossRef] [PubMed]
140. Arora, H.; Qureshi, R.; Park, W.Y. Mir-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS ONE 2013, 8, e64273. [CrossRef] [PubMed]
141. Roy-Chaudhuri, B.; Valdmanis, P.N.; Zhang, Y.; Wang, Q.; Luo, Q.J.; Kay, M.A. Regulation of microrna-mediated gene silencing by microrna precursors. Nat. Struct. Mol. Biol. 2014, 21, 825–832. [CrossRef] [PubMed]
142. He, Q.; Zhou, X.; Li, S.; Jin, Y.; Chen, Z.; Chen, D.; Cai, Y.; Liu, Z.; Zhao, T.; Wang, A. Microrna-181a suppresses salivary adenoid cystic carcinoma metastasis by targeting mapk-snai2 pathway. Biochim. Biophys. Acta. 2013, 1830, 5258–5266. [CrossRef] [PubMed]
143. Moes, M.; Le Bechec, A.; Crespo, I.; Laurini, C.; Halavatyi, A.; Vetter, G.; Del Sol, A.; Friederich, E. A novel network integrating a mirna-203/snai1 feedback loop which regulates epithelial to mesenchymal transition. PLoS ONE 2012, 7, e35440. [CrossRef] [PubMed]
144. Ding, X.; Park, S.I.; McCauley, L.K.; Wang, C.Y. Signaling between transforming growth factor beta (tgf-beta) and transcription factor snai2 represses expression of microrna mir-203 to promote epithelial-mesenchymal transition and tumor metastasis. J. Bio. Chem. 2013, 288, 10241–10253. [CrossRef] [PubMed]
145. Hamamori, Y.; Sartorelli, V.; Ogryzko, V.; Puri, P.L.; Wu, H.Y.; Wang, J.Y.; Nakatani, Y.; Kedes, L. Regulation of histone acetyltransferases p300 and pcaf by the bhlh protein twist and adenoviral oncoprotein e1a. Cell 1999, 96, 405–413. [CrossRef]
146. Castanon, I.; Von Stetina, S.; Kass, J.; Baylies, M.K. Dimerization partners determine the activity of the twist bhlh protein during drosophila mesoderm development. Development 2001, 128, 3145–3159. [PubMed]
147. Firulli, B.A.; Krawchuk, D.; Centonze, V.E.; Vargesson, N.; Virshup, D.M.; Conway, S.J.; Cserjesi, P.; Laufer, E.; Firulli, A.B. Altered twist1 and hand2 dimerization is associated with saethre-chotzen syndrome and limb abnormalities. Nat. Genet. 2005, 37, 373–381. [CrossRef] [PubMed]
148. Connerney, J.; Andreeva, V.; Leshem, Y.; Muentener, C.; Mercado, M.A.; Spicer, D.B. Twist1 dimer selection regulates cranial suture patterning and fusion. Dev. Dyn. 2006, 235, 1345–1357. [CrossRef] [PubMed]
149. Connerney, J.; Andreeva, V.; Leshem, Y.; Mercado, M.A.; Dowell, K.; Yang, X.; Lindner, V.; Friesel, R.E.; Spicer, D.B. Twist1 homodimers enhance fgf responsiveness of the cranial sutures and promote suture closure. Dev. Biol. 2008, 318, 323–334. [CrossRef] [PubMed]
150. Yang, G.; Yuan, J.; Li, K. Emt transcription factors: Implication in osteosarcoma. Med. Oncol. 2013, 30, 697. [CrossRef] [PubMed]
151. Tseng, J.C.; Chen, H.F.; Wu, K.J. A twist tale of cancer metastasis and tumor angiogenesis. Histol. Histopathol. 2015, 30, 1283–1294. [PubMed]
152. Puisieux, A.; Valsesia-Wittmann, S.; Ansieau, S. A twist for survival and cancer progression. Br. J. Cancer 2006, 94, 13–17. [CrossRef] [PubMed]
153. Norozi, F.; Ahmadzadeh, A.; Shahjahani, M.; Shahrabi, S.; Saki, N. Twist as a new prognostic marker in hematological malignancies. Clin. Transl. Oncol. 2015. [CrossRef] [PubMed]
154. Khan, M.A.; Chen, H.C.; Zhang, D.; Fu, J. Twist: A molecular target in cancer therapeutics. Tumour Biol. 2013, 34, 2497–2506. [CrossRef] [PubMed]
155. Karreth, F.; Tuveson, D.A. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol. Ther. 2004, 3, 1058–1059. [CrossRef] [PubMed]
156. Hung, J.J.; Yang, M.H.; Hsu, H.S.; Hsu, W.H.; Liu, J.S.; Wu, K.J. Prognostic significance of hypoxia-inducible factor-1alpha, twist1 and snail expression in resectable non-small cell lung cancer. Thorax 2009, 64, 1082–1089. [CrossRef] [PubMed]
157. Bourguignon, L.Y.; Wong, G.; Earle, C.; Krueger, K.; Spevak, C.C. Hyaluronan-cd44 interaction promotes c-src-mediated twist signaling, microrna-10b expression, and rhoa/rhoc up-regulation, leading to rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J. Biol. Chem. 2010, 285, 36721–36735. [CrossRef] [PubMed]
158. Haque, I.; Banerjee, S.; Mehta, S.; De, A.; Majumder, M.; Mayo, M.S.; Kambhampati, S.; Campbell, D.R.; Banerjee, S.K. Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (ccn5)/wnt-1-induced signaling protein-2 (wisp-2) regulates microrna-10b via hypoxia-inducible factor-1alpha-twist signaling networks in human breast cancer cells. J. Biol. Chem. 2011, 286, 43475–43485. [CrossRef] [PubMed]
159. Loayza-Puch, F.; Yoshida, Y.; Matsuzaki, T.; Takahashi, C.; Kitayama, H.; Noda, M. Hypoxia and ras-signaling pathways converge on, and cooperatively downregulate, the reck tumor-suppressor protein through micrornas. Oncogene 2010, 29, 2638–2648. [CrossRef] [PubMed]
160. Yin, G.; Chen, R.; Alvero, A.B.; Fu, H.H.; Holmberg, J.; Glackin, C.; Rutherford, T.; Mor, G. Twisting stemness, inflammation and proliferation of epithelial ovarian cancer cells through mir199a2/214. Oncogene 2010, 29, 3545–3553. [CrossRef] [PubMed]
161. Li, X.; Zhang, Y.; Zhang, H.; Liu, X.; Gong, T.; Li, M.; Sun, L.; Ji, G.; Shi, Y.; Han, Z., et al. Mirna-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor epb41l3. Mol. Cancer. Res. 2011, 9, 824–833. [CrossRef] [PubMed]
162. Meng, F.; Glaser, S.S.; Francis, H.; DeMorrow, S.; Han, Y.; Passarini, J.D.; Stokes, A.; Cleary, J.P.; Liu, X.; Venter, J., et al. Functional analysis of micrornas in human hepatocellular cancer stem cells. J. Cell. Mol. Med. 2012, 16, 160–173. [CrossRef] [PubMed]
163. Liu, M.; Wang, J.; Huang, H.; Hou, J.; Zhang, B.; Wang, A. Mir-181a-twist1 pathway in the chemoresistance of tongue squamous cell carcinoma. Biochem. Biophys. Res. Commun. 2013, 441, 364–370. [CrossRef] [PubMed]
164. Drasin, D.J.; Guarnieri, A.L.; Neelakantan, D.; Kim, J.; Cabrera, J.H.; Wang, C.A.; Zaberezhnyy, V.; Gasparini, P.; Cascione, L.; Huebner, K., et al. Twist1-induced mir-424 reversibly drives mesenchymal programming while inhibiting tumor initiation. Cancer Res. 2015, 75, 1908–1921. [CrossRef] [PubMed]
165. Wiklund, E.D.; Bramsen, J.B.; Hulf, T.; Dyrskjot, L.; Ramanathan, R.; Hansen, T.B.; Villadsen, S.B.; Gao, S.; Ostenfeld, M.S.; Borre, M., et al. Coordinated epigenetic repression of the mir-200 family and mir-205 in invasive bladder cancer. Int. J. Cancer. 2011, 128, 1327–1334. [CrossRef] [PubMed]
166. Chang, C.J.; Hsu, C.C.; Chang, C.H.; Tsai, L.L.; Chang, Y.C.; Lu, S.W.; Yu, C.H.; Huang, H.S.; Wang, J.J.; Tsai, C.H., et al. Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol. Rep. 2011, 26, 1003–1010. [PubMed]
167. Haga, C.L.; Phinney, D.G. Micrornas in the imprinted dlk1-dio3 region repress the epithelial-to-mesenchymal transition by targeting the twist1 protein signaling network. J. Biol. Chem. 2012, 287, 42695–42707. [CrossRef] [PubMed]
168. Nairismagi, M.L.; Vislovukh, A.; Meng, Q.; Kratassiouk, G.; Beldiman, C.; Petretich, M.; Groisman, R.; Fuchtbauer, E.M.; Harel-Bellan, A.; Groisman, I. Translational control of twist1 expression in mcf-10a cell lines recapitulating breast cancer progression. Oncogene 2012, 31, 4960–4966. [CrossRef] [PubMed]
169. Nairismagi, M.L.; Fuchtbauer, A.; Labouriau, R.; Bramsen, J.B.; Fuchtbauer, E.M. The proto-oncogene twist1 is regulated by micrornas. PLoS ONE 2013, 8, e66070. [CrossRef] [PubMed]
170. Li, L.Z.; Zhang, C.Z.; Liu, L.L.; Yi, C.; Lu, S.X.; Zhou, X.; Zhang, Z.J.; Peng, Y.H.; Yang, Y.Z.; Yun, J.P. Mir-720 inhibits tumor invasion and migration in breast cancer by targeting twist1. Carcinogenesis 2014, 35, 469–478. [CrossRef] [PubMed]
171. Hernandez, J.M.; Elahi, A.; Clark, C.W.; Wang, J.; Humphries, L.A.; Centeno, B.; Bloom, G.; Fuchs, B.C.; Yeatman, T.; Shibata, D. Mir-675 mediates downregulation of twist1 and rb in afp-secreting hepatocellular carcinoma. Ann. Surg. Oncol. 2013, 20, S625–S635. [CrossRef] [PubMed]
172. Tsukerman, P.; Yamin, R.; Seidel, E.; Khawaled, S.; Schmiedel, D.; Bar-Mag, T.; Mandelboim, O. Mir-520d-5p directly targets twist1 and downregulates the metastamir mir-10b. Oncotarget 2014, 5, 12141–12150. [CrossRef] [PubMed]
173. Liu, S.; Cui, J.; Liao, G.; Zhang, Y.; Ye, K.; Lu, T.; Qi, J.; Wan, G. Mir-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor. Tumour Biol. 2014, 35, 9131–9138. [CrossRef] [PubMed]
174. Zhou, Y.; Huang, Z.; Wu, S.; Zang, X.; Liu, M.; Shi, J. Mir-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating twist. J. Exp. Clin. Cancer Res. 2014, 33, 12. [CrossRef] [PubMed]
175. Yang, L.; Yang, J.; Li, J.; Shen, X.; Le, Y.; Zhou, C.; Wang, S.; Zhang, S.; Xu, D.; Gong, Z. Mircorna-33a inhibits epithelial-to-mesenchymal transition and metastasis and could be a prognostic marker in non-small cell lung cancer. Sci. Rep. 2015, 5, 13677. [CrossRef] [PubMed]
176. Zhu, X.; Shen, H.; Yin, X.; Long, L.; Xie, C.; Liu, Y.; Hui, L.; Lin, X.; Fang, Y.; Cao, Y., et al. Mir-186 regulation of twist1 and ovarian cancer sensitivity to cisplatin. Oncogene 2015
177. Chang, Y.S.; Chen, W.Y.; Yin, J.J.; Sheppard-Tillman, H.; Huang, J.; Liu, Y.N. Egf receptor promotes prostate cancer bone metastasis by downregulating mir-1 and activating twist1. Cancer Res. 2015, 75, 3077–3086. [CrossRef] [PubMed]
178. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704–715. [CrossRef] [PubMed]
179. Morel, A.P.; Lievre, M.; Thomas, C.; Hinkal, G.; Ansieau, S.; Puisieux, A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3, e2888. [CrossRef] [PubMed]
180. Wellner, U.; Schubert, J.; Burk, U.C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A., et al. The emt-activator zeb1 promotes tumorigenicity by repressing stemness-inhibiting micrornas. Nat. Cell. Biol. 2009, 11, 1487–1495. [CrossRef] [PubMed]
181. Schepers, G.E.; Teasdale, R.D.; Koopman, P. Twenty pairs of sox: Extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev. Cell 2002, 3, 167–170. [CrossRef]
182. Stolt, C.C.; Wegner, M. Soxe function in vertebrate nervous system development. Int. J. Biochem. Cell. Biol 2010, 42, 437–440. [CrossRef] [PubMed]
183. Guth, S.I.; Bosl, M.R.; Sock, E.; Wegner, M. Evolutionary conserved sequence elements with embryonic enhancer activity in the vicinity of the mammalian sox8 gene. Int. J. Biochem. Cell. Biol. 2010, 42, 465–471. [CrossRef] [PubMed]
184. Wegner, M. All purpose sox: The many roles of sox proteins in gene expression. Int. J. Biochem. Cell. Biol. 2010, 42, 381–390. [CrossRef] [PubMed]
185. Sakai, D.; Suzuki, T.; Osumi, N.; Wakamatsu, Y. Cooperative action of sox9, snail2 and pka signaling in early neural crest development. Development 2006, 133, 1323–1333. [CrossRef] [PubMed]
186. Suske, G.; Bruford, E.; Philipsen, S. Mammalian sp/klf transcription factors: Bring in the family. Genomics 2005, 85, 551–556. [CrossRef] [PubMed]
187. Pearson, R.; Fleetwood, J.; Eaton, S.; Crossley, M.; Bao, S. Kruppel-like transcription factors: A functional family. Int. J. Biochem. Cell. Biol. 2008, 40, 1996–2001. [CrossRef] [PubMed]
188. Chambers, I.; Colby, D.; Robertson, M.; Nichols, J.; Lee, S.; Tweedie, S.; Smith, A. Functional expression cloning of nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003, 113, 643–655. [CrossRef]
189. Sureban, S.M.; May, R.; Qu, D.; Weygant, N.; Chandrakesan, P.; Ali, N.; Lightfoot, S.A.; Pantazis, P.; Rao, C.V.; Postier, R.G., et al. Dclk1 regulates pluripotency and angiogenic factors via microrna-dependent mechanisms in pancreatic cancer. PLoS One 2013, 8, e73940. [CrossRef] [PubMed]
190. Sureban, S.M.; May, R.; Weygant, N.; Qu, D.; Chandrakesan, P.; Bannerman-Menson, E.; Ali, N.; Pantazis, P.; Westphalen, C.B.; Wang, T.C., et al. Xmd8-92 inhibits pancreatic tumor xenograft growth via a dclk1-dependent mechanism. Cancer Lett. 2014, 351, 151–161. [CrossRef] [PubMed]
191. Xia, Y.; Wu, Y.; Liu, B.; Wang, P.; Chen, Y. Downregulation of mir-638 promotes invasion and proliferation by regulating sox2 and induces emt in nsclc. FEBS Lett. 2014, 588, 2238–2245. [CrossRef] [PubMed]
192. Chan, K.C.; Chan, L.S.; Ip, J.C.; Lo, C.; Yip, T.T.; Ngan, R.K.; Wong, R.N.; Lo, K.W.; Ng, W.T.; Lee, A.W., et al. Therapeutic targeting of cbp/beta-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of ebv-positive nasopharyngeal carcinoma cells with cisplatin. Sci. Rep. 2015, 5, 9979. [CrossRef] [PubMed]
193. Li, Y.; Lv, Z.; He, G.; Wang, J.; Zhang, X.; Lu, G.; Ren, X.; Wang, F.; Zhu, X.; Ding, Y., et al. The sox17/mir-371-5p/sox2 axis inhibits emt, stem cell properties and metastasis in colorectal cancer. Oncotarget 2015, 6, 9099–9112. [CrossRef] [PubMed]
194. Zhou, A.D.; Diao, L.T.; Xu, H.; Xiao, Z.D.; Li, J.H.; Zhou, H.; Qu, L.H. Beta-catenin/lef1 transactivates the microrna-371-373 cluster that modulates the wnt/beta-catenin-signaling pathway. Oncogene 2012, 31, 2968–2978. [CrossRef] [PubMed]
195. Hahn, S.; Hermeking, H. Znf281/zbp-99: A new player in epithelial-mesenchymal transition, stemness, and cancer. J. Mol. Med. (Berl.) 2014, 92, 571–581. [CrossRef] [PubMed]
196. Ocana, O.H.; Corcoles, R.; Fabra, A.; Moreno-Bueno, G.; Acloque, H.; Vega, S.; Barrallo-Gimeno, A.; Cano, A.; Nieto, M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer prrx1. Cancer Cell 2012, 22, 709–724. [CrossRef] [PubMed]
197. Zhang, Y.; Zheng, L.; Huang, J.; Gao, F.; Lin, X.; He, L.; Li, D.; Li, Z.; Ding, Y.; Chen, L. Mir-124 radiosensitizes human colorectal cancer cells by targeting prrx1. PLoS ONE 2014, 9, e93917. [CrossRef] [PubMed]
198. Xiang, X.; Zhuang, X.; Ju, S.; Zhang, S.; Jiang, H.; Mu, J.; Zhang, L.; Miller, D.; Grizzle, W.; Zhang, H.G. Mir-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing emt. Oncogene 2011, 30, 3440–3453. [CrossRef] [PubMed]